MoonLake Immunotherapeutics (MLTX, $50.23) was a top loser over the last three months, falling -1 to $50.23 per share. A.I.dvisor analyzed 869 stocks in the Biotechnology Industry for the 3-month period ending March 28, 2024, and found that of them (6) exhibited an Uptrend while of them (3) demonstrated a Downtrend.